Climb Bio, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	March 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$29,020	$87,229
Short-term marketable securities	69,042	63,690
Prepaid expenses and other current assets	2,218	3,953
Total current assets	$100,280	$154,872
Operating lease right-of-use assets	451	490
Long-term marketable securities	99,783	61,610
Other long-term assets	226	215
Total assets	$200,740	$217,187
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$777	$705
Accrued expenses and other current liabilities	6,104	4,069
Operating lease liabilities	155	157
Total current liabilities	$7,036	$4,931
Operating lease liabilities, net of current portion	319	375
Total liabilities	$7,355	$5,306
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 67,575,767 and 67,255,434 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	7	7
Additional paid-in capital	443,749	441,727
Accumulated other comprehensive income	286	23
Accumulated deficit	(250,657)	(229,876)
Total stockholders’ equity	$193,385	$211,881
Total liabilities and stockholders’ equity	$200,740	$217,187

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.